Trimethoprim-sulphamethoxazole in acute brucellosis.
Eight patients with proved brucella infection were treated with trimethoprim-sulphamethoxazole. The dose varied from two to four tablets given twice daily for three weeks. Clinical response was rapid and all patients were asymptomatic and afebrile within two to seven days of starting therapy. Three patients relapsed clinically and bacteriologically within three weeks of ending treatment. There were no side effects of the treatment. It is suggested that the treatment be continued for at least six weeks to prevent relapses.
D000293:Adolescent; D000328:Adult; D002006:Brucellosis / Q000188:drug therapy*; D002648:Child; D004357:Drug Synergism; D005260:Female; D005493:Folic Acid Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D055502:Secondary Prevention; D013420:Sulfamethoxazole / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D005493:Folic Acid Antagonists; D011743:Pyrimidines; D013420:Sulfamethoxazole